𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gliomatosis cerebri: Results with radiation therapy

✍ Scribed by Scott C. Cozad; Patrick Townsend; Robert A. Morantz; Arthur B. Jenny; John J. Kepes; Stephen R. Smalley

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
499 KB
Volume
78
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Background:

This review was undertaken to determine the outcome for patients diagnosed in the modern era and treated with radiation therapy.

Methods:

Using the tumor registries of six institutions in a large metropolitan area, cases of gliomatosis were identified and retrospectively reviewed.

Results:

The clinical course for each patient was unique. deterioration during treatment, brief stabilization, and reversal of the clinical signs and symptoms with stability and high quality of life at 16 months from diagnosis characterized patients 1, 2, and 3, respectively.

Conclusions:

Radiotherapy for gliomatosis appears to stabilize or improve neurologic function in some patients. its impact on survival will await additional reports and longer follow-up.

πŸ“œ SIMILAR VOLUMES

Gliomatosis cerebri : Treatment results
Gliomatosis cerebri : Treatment results with radiotherapy alone
✍ Mohamed A. Elshaikh; Glen H.J. Stevens; David M. Peereboom; Bruce H. Cohen; Rich πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 64 KB

## Background: Gliomatosis cerebri (gc) is a rare primary brain tumor characterized by proliferation of neoplastic glial cells that typically involve multiple brain areas, with preservation of brain structures and sparing of neurons. the optimal therapeutic strategy is not well established. the imp

Response to low dose temozolomide in rad
Response to low dose temozolomide in radiation induced gliomatosis cerebri
✍ Hargrave, D. ;Bouffet, E. ;Gammon, J. ;Becker, L. ;Rutka, J. ;Baruchel, S. πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 109 KB

{ Sylvain Baruchel is the Principal Investigator of an industry sponsored study (Schering-Plough). He receives no monetary compensation. Grant sponsor: Temodal 1 (the manufacturers of temozolomide), Schering Plough, Inc. (for the Phase I Clinical Trial).